|
Name |
Notoamide C
|
Molecular Formula | C26H31N3O4 | |
IUPAC Name* |
(3S,8aS)-3-[[(3S)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1H-pyrano[2,3-g]indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC1(C=CC2=C(O1)C=CC3=C2NC(=O)[C@@]3(C[C@H]4C(=O)N5CCC[C@H]5C(=O)N4)C(C)(C)C=C)C
|
|
InChI |
InChI=1S/C26H31N3O4/c1-6-24(2,3)26(14-17-22(31)29-13-7-8-18(29)21(30)27-17)16-9-10-19-15(20(16)28-23(26)32)11-12-25(4,5)33-19/h6,9-12,17-18H,1,7-8,13-14H2,2-5H3,(H,27,30)(H,28,32)/t17-,18-,26-/m0/s1
|
|
InChIKey |
KNFZHRYXLWKRSU-XWXLMPLOSA-N
|
|
Synonyms |
Notoamide C; C3-Epi-notoamide C; 3-epi-Notamide C; CHEMBL2332633; CHEBI:145685; NSC784313; NSC-784313; (3S,8aS)-3-[[(3S)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1H-pyrano[2,3-g]indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; (3S,8aS)-3-{[(3S)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1,2,3,7-tetrahydropyrano[2,3-g]indol-3-yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; 937251-97-3
|
|
CAS | NA | |
PubChem CID | 25163938 | |
ChEMBL ID | CHEMBL2332633 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 449.5 | ALogp: | 3.1 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.7 | Aromatic Rings: | 5 |
Heavy Atoms: | 33 | QED Weighted: | 0.682 |
Caco-2 Permeability: | -4.865 | MDCK Permeability: | 0.00003340 |
Pgp-inhibitor: | 0.994 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.051 | 20% Bioavailability (F20%): | 0.058 |
30% Bioavailability (F30%): | 0.042 |
Blood-Brain-Barrier Penetration (BBB): | 0.492 | Plasma Protein Binding (PPB): | 90.81% |
Volume Distribution (VD): | 0.785 | Fu: | 4.83% |
CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.406 |
CYP2C19-inhibitor: | 0.124 | CYP2C19-substrate: | 0.828 |
CYP2C9-inhibitor: | 0.285 | CYP2C9-substrate: | 0.918 |
CYP2D6-inhibitor: | 0.034 | CYP2D6-substrate: | 0.213 |
CYP3A4-inhibitor: | 0.912 | CYP3A4-substrate: | 0.901 |
Clearance (CL): | 2.077 | Half-life (T1/2): | 0.168 |
hERG Blockers: | 0.111 | Human Hepatotoxicity (H-HT): | 0.64 |
Drug-inuced Liver Injury (DILI): | 0.193 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.879 | Maximum Recommended Daily Dose: | 0.922 |
Skin Sensitization: | 0.051 | Carcinogencity: | 0.919 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.904 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003156 | 0.736 | D0Q5NX | 0.252 | ||||
ENC002365 | 0.583 | D02IQY | 0.250 | ||||
ENC004604 | 0.531 | D06YFA | 0.243 | ||||
ENC004064 | 0.465 | D0U7GK | 0.231 | ||||
ENC003322 | 0.457 | D01TSI | 0.230 | ||||
ENC002052 | 0.457 | D0A3ZU | 0.227 | ||||
ENC002366 | 0.452 | D0V3ZA | 0.223 | ||||
ENC002536 | 0.452 | D06XZW | 0.221 | ||||
ENC002534 | 0.452 | D09ZIO | 0.220 | ||||
ENC004933 | 0.451 | D0SP3D | 0.217 |